Brief: Diamedica Therapeutics Announces Regulatory Approval To Begin Phase 2 Trial Of Dm199
09/10/2024 13:35
Oct 9 (Reuters) - DiaMedica Therapeutics Inc DMAC.O :
* DIAMEDICA THERAPEUTICS ANNOUNCES REGULATORY APPROVAL TO
BEGIN
PHASE 2 TRIAL OF DM199 IN THE TREATMENT OF PREECLAMPSIA
* DIAMEDICA THERAPEUTICS INC - DOSING TO BEGIN IN Q4 2024,
RESULTS
EXPECTED H1 2025
* DIAMEDICA THERAPEUTICS INC - SAHPRA APPROVES PHASE 2 STUDY
FOR
PREECLAMPSIA IN SOUTH AFRICA
* DIAMEDICA THERAPEUTICS INC - TOP-LINE RESULTS FOR PART 1A
EXPECTED IN H1 2025
Source text for Eikon: ID:nBw1gj123a
Further company coverage: DMAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program